DE2423811A1 - Verfahren zur herstellung von gefriergetrockneten 2,2'-anhydro-1-beta-d-arabinofuranosylcytosin-praeparaten und injektionspraeparat - Google Patents
Verfahren zur herstellung von gefriergetrockneten 2,2'-anhydro-1-beta-d-arabinofuranosylcytosin-praeparaten und injektionspraeparatInfo
- Publication number
- DE2423811A1 DE2423811A1 DE2423811A DE2423811A DE2423811A1 DE 2423811 A1 DE2423811 A1 DE 2423811A1 DE 2423811 A DE2423811 A DE 2423811A DE 2423811 A DE2423811 A DE 2423811A DE 2423811 A1 DE2423811 A1 DE 2423811A1
- Authority
- DE
- Germany
- Prior art keywords
- weight
- freeze
- dried
- preparations
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 38
- 238000000034 method Methods 0.000 title claims description 18
- 238000002347 injection Methods 0.000 title description 14
- 239000007924 injection Substances 0.000 title description 14
- 238000004519 manufacturing process Methods 0.000 title description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000007864 aqueous solution Substances 0.000 claims description 21
- 238000004108 freeze drying Methods 0.000 claims description 15
- 239000012153 distilled water Substances 0.000 claims description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 239000000600 sorbitol Substances 0.000 claims description 11
- 235000010356 sorbitol Nutrition 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- -1 cytosine compound Chemical class 0.000 claims description 10
- 229920002307 Dextran Polymers 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 4
- 229940104302 cytosine Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229920005682 EO-PO block copolymer Polymers 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 229950000242 ancitabine Drugs 0.000 description 33
- KZOWNALBTMILAP-JBMRGDGGSA-N ancitabine hydrochloride Chemical compound Cl.N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 KZOWNALBTMILAP-JBMRGDGGSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 28
- 239000011521 glass Substances 0.000 description 23
- 239000000654 additive Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 230000035699 permeability Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- HLHOHTNONYACFD-UHFFFAOYSA-N 1-[4-[4-morpholin-4-yl-1-[1-(pyridine-3-carbonyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-3-pyridin-4-ylurea Chemical compound C=1C=C(C=2N=C3N(C4CCN(CC4)C(=O)C=4C=NC=CC=4)N=CC3=C(N3CCOCC3)N=2)C=CC=1NC(=O)NC1=CC=NC=C1 HLHOHTNONYACFD-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5414573A JPS5637967B2 (enrdf_load_stackoverflow) | 1973-05-17 | 1973-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2423811A1 true DE2423811A1 (de) | 1974-12-05 |
Family
ID=12962379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2423811A Pending DE2423811A1 (de) | 1973-05-17 | 1974-05-16 | Verfahren zur herstellung von gefriergetrockneten 2,2'-anhydro-1-beta-d-arabinofuranosylcytosin-praeparaten und injektionspraeparat |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS5637967B2 (enrdf_load_stackoverflow) |
| DE (1) | DE2423811A1 (enrdf_load_stackoverflow) |
| ES (1) | ES426414A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2229416A1 (enrdf_load_stackoverflow) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2658406A1 (de) * | 1975-12-31 | 1977-07-07 | Asahi Chemical Ind | Arzneimittelzubereitungen mit verbesserter loeslichkeit und ihre herstellung |
| WO1998029100A1 (en) * | 1996-12-31 | 1998-07-09 | Korea Institute Of Science And Technology | Method of manufacturing porous matrix-type controlled release systems using emulsion technique |
| WO1999002542A1 (en) * | 1997-07-11 | 1999-01-21 | Astra Pharmaceuticals Ltd. | New formulation |
| US6114313A (en) * | 1996-12-20 | 2000-09-05 | Astra Zeneca Uk Limited | Pharmaceutical compositions for freeze drying |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51139613A (en) * | 1975-05-24 | 1976-12-02 | Nippon Shinyaku Co Ltd | An absorbable non-crystalline sterol glycoside monopalmitate ester and a method for preparing its pharmaceutical |
| GB8426922D0 (en) * | 1984-10-24 | 1984-11-28 | Sandoz Ltd | Galenic formulation |
| US6417167B1 (en) | 1997-02-05 | 2002-07-09 | Kirin Beer Kabushiki Kaisha | Lyophilized compositions containing shingoglycolipid and process for preparing them |
| KR100301890B1 (ko) * | 1997-02-05 | 2002-01-09 | 사토 야스히로 | 스핀고당지질을함유하는동결건조조성물및그의제조방법 |
-
1973
- 1973-05-17 JP JP5414573A patent/JPS5637967B2/ja not_active Expired
-
1974
- 1974-05-16 DE DE2423811A patent/DE2423811A1/de active Pending
- 1974-05-17 ES ES426414A patent/ES426414A1/es not_active Expired
- 1974-05-17 FR FR7417294A patent/FR2229416A1/fr not_active Withdrawn
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2658406A1 (de) * | 1975-12-31 | 1977-07-07 | Asahi Chemical Ind | Arzneimittelzubereitungen mit verbesserter loeslichkeit und ihre herstellung |
| US6114313A (en) * | 1996-12-20 | 2000-09-05 | Astra Zeneca Uk Limited | Pharmaceutical compositions for freeze drying |
| RU2205012C2 (ru) * | 1996-12-20 | 2003-05-27 | Астра Фармасьютикалз Лтд. | Фармацевтические композиции для сушки вымораживанием |
| WO1998029100A1 (en) * | 1996-12-31 | 1998-07-09 | Korea Institute Of Science And Technology | Method of manufacturing porous matrix-type controlled release systems using emulsion technique |
| GB2336110A (en) * | 1996-12-31 | 1999-10-13 | Korea Inst Sci & Tech | Method of manufacturing porous matrix-type controlled release systems using emulsion technique |
| GB2336110B (en) * | 1996-12-31 | 2000-10-18 | Korea Inst Sci & Tech | Method of manufacturing porous matrix-type controlled release systems using emulsion technique |
| WO1999002542A1 (en) * | 1997-07-11 | 1999-01-21 | Astra Pharmaceuticals Ltd. | New formulation |
| US6130208A (en) * | 1997-07-11 | 2000-10-10 | Astrazeneca Uk Limited | Formulation containing a nucleotide analogue |
| RU2216330C2 (ru) * | 1997-07-11 | 2003-11-20 | Астра Фармасьютикалз Лтд. | Фармацевтическая композиция, содержащая нуклеотидный аналог, и способ ее приготовления |
| CZ298110B6 (cs) * | 1997-07-11 | 2007-06-27 | Astrazeneca Uk Limited | Lyofilizovaná, ve spreji susená nebo vakuove susená farmaceutická kompozice a zpusob její výroby |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2229416A1 (en) | 1974-12-13 |
| JPS5637967B2 (enrdf_load_stackoverflow) | 1981-09-03 |
| ES426414A1 (es) | 1976-07-01 |
| JPS505523A (enrdf_load_stackoverflow) | 1975-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69223624T2 (de) | Taxan-derivate enthaltende arzneimittel | |
| DE60132108T2 (de) | Gefriergetrocknetes pantoprazol-präparat und pantoprazol-injektion | |
| DE60034445T2 (de) | Gefriergetrocknete hgf-präparationen | |
| DE60011149T2 (de) | Klare wässrige anästhesierende zusammensetzung | |
| DE69421936T2 (de) | Stabilisiertes prostaglandin e1 | |
| DE3346123A1 (de) | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung | |
| DE69230672T2 (de) | Gonadotropin, das pharmazeutische zusammensetzungen mit sucrose stabilisator enthält | |
| EP0806955B1 (de) | Enrofloxacin-injektions- oder infusionslösungen | |
| DE2219635C3 (de) | Insulinsalz-Protamin-Komplexe und Verfahren zu ihrer Herstellung | |
| DE60005376T2 (de) | Oxaliplatinhaltige parenteral anzuwendende stabilisierte arzneizubereitung und verfahren zu deren herstellung | |
| EP0334083A1 (de) | Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung | |
| EP0407804B1 (de) | Wasserlösliche pharmazeutische Metallocen-Komplex-Zusammensetzung | |
| DE2323187C2 (de) | Verfahren zur Herstellung einer stabilisierten, pulverförmigen Secretinzubereitung | |
| DE2752443C2 (de) | Verfahren zur Herstellung von Cefazolin-Natrium | |
| DE2423811A1 (de) | Verfahren zur herstellung von gefriergetrockneten 2,2'-anhydro-1-beta-d-arabinofuranosylcytosin-praeparaten und injektionspraeparat | |
| DD209392A5 (de) | Verfahren zur herstellung von sterilen zubereitungen hochviskoser loesungen und substanzen | |
| DE60009926T2 (de) | Stabilisierung von gefriergetrocknetem kuchen | |
| DE2515001C2 (de) | Prostaglandin enthaltende gefriergetrocknete Pulver | |
| DE19529057A1 (de) | Ifosfamid-Lyophilisat-Zubereitungen | |
| DE2415936C2 (enrdf_load_stackoverflow) | ||
| DE2834702A1 (de) | Von mineralsalzen, insbesondere oxalaten, befreite heparinpraeparate, verfahren zu ihrer herstellung und ihre verwendung | |
| DE3119510C2 (enrdf_load_stackoverflow) | ||
| DE69831223T9 (de) | Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52 | |
| DE2441761A1 (de) | Gefriergetrocknete 2,2'-anhydro1-beta-d-arabinofuranosylcytosinsalz-praeparate, verfahren zu ihrer herstellung und injektionspraeparat | |
| DE3142853A1 (de) | Feste arzneizubereitungen mit nifedipin und verfahren zu ihrer herstellung |